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Précis: Noninferiority of efficacy was demonstrated for a preser-
vative-free latanoprost-timolol fixed combination compared with a
BAK-containing formulation at 84 days after treatment in patients
with open-angle glaucoma or ocular hypertension.
Purpose: The purpose of this study was to compare the effect on
intraocular pressure and safety of preservative-free latanoprost-
timolol fixed combination (T2347) to benzalkonium chloride-pre-
served latanoprost-timolol fixed combination in patients with
open-angle glaucoma or ocular hypertension.
Methods: Phase III, randomized, parallel-group, investigator-
masked study in 10 countries. A total of 242 patients aged 18 years
or older with open-angle glaucoma or ocular hypertension in both
eyes controlled with a preserved latanoprost-timolol fixed combi-
nation (15.7 ± 2.4 mmHg overall before inclusion) were random-
ized at day 0 with no washout period to receive the preservative-
free alternative T2347 (N= 127) or remain on the preserved
comparator (N= 115) for 84 days. Intraocular pressure changes
from day 0 were measured at 9:00 am ( ± 1 hour) on day 42 and
day 84, and noninferiority of T2347 to the preserved comparator
was analyzed statistically at day 84. Safety parameters were also
reported.
Results: The mean change in intraocular pressure from baseline to
day 84 was −0.49± 1.80mmHg for preservative-free T2347 and
−0.49± 2.25mmHg for the preserved comparator. These results
met the noninferiority limits. Similar results were observed at day
42. There was no difference between groups in the incidence of
adverse events or ocular signs. The total ocular symptoms score was
better for T2347 than BPLT upon instillation at day 84 (45.9%/
44.3%/9.8% of patients with improvement/no change/worsening vs.
33.6%/47.3%/19.1%; P= 0.021), reflecting improvements in indi-
vidual symptoms such as irritation/burning/stinging (P< 0.001), and
itching (P< 0.01) on day 84.
Conclusions: Preservative-free latanoprost-timolol fixed combina-
tion T2347 showed noninferior efficacy compared with the pre-
served comparator and was well tolerated.
Key Words: glaucoma, ocular hypertension, preservative-free,
latanoprost-timolol
(J Glaucoma 2019;28:498–506)
Received for publication November 19, 2018; accepted March 2, 2019.
From the *CHU de Grenoble/University Hospital of Grenoble, Université Grenoble Alpes, Grenoble; ∥∥Centre Hospitalier du Pays d’Aix, Service
Ophtalmologie, Aix-en-Provence; ¶¶Ophthalmology, CHNO des Quinze-Vingts, Paris, France; †Department of Ophthalmology, Mainz University
Medical Center, Mainz; ‡Augen-Zentrum-Nordwest, Augenpraxis Ahaus, Ahaus, Germany; §NIHR Biomedical Research Centre for Ophthalmology,
Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK; ∥Hospital Universitario La Paz, Madrid; ¶Clínica Universidad de
Navarra, Pamplona, Spain; #Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin, Poland; **Department of
Ophthalmology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; ††Clinic of Ophthalmology, Tallinn, Estonia; ‡‡Dr Volksone’s
Practice in Ophthalmology, Lavolks Ltd, Riḡa, Latvia; §§Department of Ophthalmology, Academician I.P. Pavlov First St. Petersburg State Medical
University, St. Petersburg, Russia; and ##Department of Ophthalmology, University Hospitals UZ Leuven, Leuven, Belgium.
Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Baltimore, MD, May 7-11, 2017, and at the
World Glaucoma Congress, Helsinki, Finland, June 28-July 1, 2017.
F.A.: study design, literature search, data analysis, and evidence synthesis, and drafting and revising of the manuscript. I.S.: study design, data collection
and screening, data analysis and evidence synthesis, and drafting and revising the manuscript. N.P., S.S., J.C., C.L.-D., J.M.-M., T.Ż., A.C., T.J.,
L.V., Y.S.A., L.C., and J.-P.N.: study design, data collection, screening, and revising of the manuscript.
Sponsored by Laboratoires Théa, Clermont-Ferrand, France, which also provided funding for medical writing assistance for this manuscript. The sponsor
participated in study design, study conduct, data collection, data management, data analysis, interpretation of the data, and preparation of the manuscript.
Disclosure: F.A. is a consultant for, and has received nonfinancial support from, Laboratoires Théa. S.S. and J.C. are consultants for, or have received a research
grant and nonfinancial support from Laboratoires Théa and were investigators in this study. J.P.N. is a consultant for, or has received a research grant and
nonfinancial from Laboratoires Théa and Allergan, and was an investigator in this study. I.S. is a consultant for, or has received a research grant and
nonfinancial support from Laboratoires Théa, Allergan, Eyetech Care, Alcon, and Santen, and was an investigator in this study. N.P., C.L.-D., J.M.-M.,
T.Ż., A.C., T.J., L.V., Y.S.A., L.C., have received a research grant and nonfinancial support from Laboratoires Théa and were investigators in this study.
Reprints: Ingeborg Stalmans, MD, PhD, University Hospitals UZ Leuven, Department of Ophthalmology Herestraat 49, 3000 Leuven, Belgium
(e-mail: ingeborg.stalmans@uzleuven.be).
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF
versions of this article on the journal’s website, www.glaucomajournal.com.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work
provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
DOI: 10.1097/IJG.0000000000001248
ORIGINAL STUDY
498 | www.glaucomajournal.com J Glaucoma  Volume 28, Number 6, June 2019
T opical eye drop formulations containing prostaglandinanalogues or β-blockers are routinely used as a first-line
treatment to prevent glaucoma progression by reducing
intraocular pressure (IOP).1 However, in 40% to 75% of
open-angle glaucoma (OAG) patients, monotherapy fails to
achieve a satisfactory reduction in IOP after > 2 years of
treatment, and combined therapy is needed.2 The admin-
istration of separate component medications could be
associated with reduced patient compliance to the treatment
schedule as the number of instillations increases.3–6 More-
over, subsequent treatments given in this way can lead to
washout of the previous one. Both of these factors lead to
reduced efficacy of unfixed combined treatments.7,8
Fixed combination formulations offer improved con-
venience, adherence to the treatment regimen, and effective-
ness as well as cost reductions.9–13 Clinical studies with a fixed
combination of latanoprost 0.005% and timolol 0.5% have
demonstrated its suitability in patients with OAG or ocular
hypertension (OHT) with better efficacy than either compo-
nent administered alone.14–17 Because of these advantages, the
use of fixed combinations has been recommended by the
European Glaucoma Society1 and is preferred over unfixed
combinations in many countries.
Clinical studies with formulations containing benzalko-
nium chloride (BAK), an antimicrobial preservative,18,19 have
shown a higher incidence of ocular symptoms compared with
preservative-free formulations and a clear association of the
preservative with the occurrence and severity of ocular prob-
lems such as corneal toxicity and conjunctival damage.20–22
An alternative preservative to BAK including boric acid and
zinc chloride has been used in a latanoprost-timolol fixed
combination formulation with similar efficacy and no differ-
ence in the incidence of treatment-emergent adverse events.23
However, the development of preservative-free combination
formulations is considered to be an important goal, and the
European Medicines Agency issued a public statement on
ophthalmic formulations that “for long-term treatment, for-
mulations without preservatives are considered to be val-
uable.”24 Preservative-free latanoprost-timolol fixed combi-
nation formulations, such as T2347, are expected to be better
tolerated than BAK-preserved latanoprost-timolol for-
mulations over the long term. This is particularly relevant for
glaucoma patients, who have a higher prevalence of ocular
surface disease than the general population,1 and for whom
improved tolerability can be associated with better compliance
and therefore improved long-term effectiveness.9,20 Better
tolerability of preservative-free formulations has a positive
impact on patient quality of life. In addition, the stability at
room temperature of eye drops such as preservative-free
T2347 removes the need for cold-chain storage, which may
further improve treatment convenience and compliance.23,25
As glaucoma requires daily, long-term IOP-lowering
treatment and preserved formulations are associated with
tolerability issues, this study was performed to establish the
noninferiority of the efficacy of T2347 compared with a
BAK-preserved latanoprost-timolol (BPLT) fixed combi-
nation after 84 days of treatment in patients who had pre-
viously been receiving the preserved formulation, and also
to compare their safety and tolerability profiles.
MATERIALS AND METHODS
Study Design and Patients
This was a phase III, international, randomized, parallel-
group, investigator-masked study in 47 centers in 10 countries—
Belgium (3 centers), Estonia (3), France (5), Germany (5),
Hungary (4), Latvia (1), Poland (7), Russia (3), Spain (11), and
the United Kingdom (5). The study was conducted in com-
pliance with Good Clinical Practice (ICH-E6), the ethical prin-
ciples of the Declaration of Helsinki (2004), and applicable local
legislation. Before enrollment, written informed consent was
obtained from each patient. The study took place between
December 2014 and November 2015 (ClinicalTrials.gov identi-
fier: NCT02278614).
Patients aged 18 years or older with OAG or OHT in
both eyes that were already treated and well-controlled for
at least 2 months before study entry with latanoprost
0.005% and timolol 0.5% fixed combination preserved eye
drops (any brand) were eligible for inclusion if the following
criteria were fulfilled: IOP ≤ 18mmHg in both eyes at the
inclusion visit, a history of IOP insufficiently controlled with
first-line monotherapy and a history of additional IOP
reduction following a switch to latanoprost 0.005% and
timolol 0.5% fixed combination preserved eye drops
(Table 1), and corneal thickness of 500 to 600 µm in
both eyes.
The main ophthalmic exclusion criteria included sig-
nificant worsening between the last 2 visual field assessments
(≥ 6mo between assessments); severe stage of glaucoma;
best-corrected far visual acuity ≤ 1/10 in at least one eye;
ocular infection, trauma, or inflammation in the previous
3 months; presence of at least one severe objective sign
[McMonnies maximum (grade 5) conjunctival hyperemia or
maximum (grade 3) blepharitis]; diagnosed severe dry eye;
corneal ulceration; palpebral abnormalities; and any other
abnormality that could prevent accurate study assessments.
Other exclusion criteria included history of corneal refrac-
tive surgery; intraocular laser procedures (3 mo before or
during the study); other ocular surgery (6 mo before and
during the study); any topical ocular treatment (except
preservative-free artificial tears or preservative-free anti-
allergic eye drops); and use of contact lenses (for 1 wk before
or during the study).
At day 0 (D0, inclusion), patients were randomized to
either receive a preservative-free fixed combination of lata-
noprost 0.005% and timolol 0.5% [T2347 (Fixaprost),
presented in single-dose units; Laboratoires Théa, Clermont-
Ferrand, France] or to continue with a BAK-preserved for-
mulation [BPLT (Xalacom), containing 0.2mg/mL BAK,
presented in multidose bottles; Pfizer, New York, NY] with-
out a washout period. The randomized code was generated by
Lincoln (Boulogne-Billancourt, France), using random per-
muted blocks with a fixed block size of 4, in a 1:1 ratio. All
eligible subjects were assigned the sequential randomization
number available at the site. To ensure investigator-masking,
personnel other than the investigator dispensed all study
treatments. Patients were to instill one drop in each eye at 9
pm (±1 h) daily for 84 days. Follow-up visits took place at
the study site at D42±3 days (D42) and D84±7 days (D84).
Efficacy Assessments
Primary Efficacy Variable
The primary efficacy variable was the change in mean
IOP from D0 to D84 measured using a calibrated Gold-
mann applanation tonometer at 9 am (± 1 h) in the worse
eye (ie, the eye with the highest IOP or the right eye if IOP
was the same in both eyes). Two measurements were taken;
if these differed by > 2 mmHg, a third reading was taken.
The average value was used in the analysis.
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Secondary Efficacy Variables
Secondary efficacy variables were IOP in the contra-
lateral eye at D84 and in both eyes at D42. In addition, the
investigator rated global efficacy on D42 and D84 (very sat-
isfactory, satisfactory, not very satisfactory, or unsatisfactory).
Safety Assessments
Adverse Events
Ocular and systemic adverse events (AEs) and their severity
(mild, moderate, or severe) were recorded at D42 and D84. The
investigator determined the potential relatedness of each AE to
the study treatment (none, unlikely, possible, or definite).
Other Safety Assessments
Other safety outcome measures, separate to the AE
reporting, included patient-assessed prelisted ocular symptoms
upon instillation and throughout the day [irritation/burning/
stinging, itching, tearing, foreign body sensation, and eye
dryness sensation; each was graded using a 4-point severity
score as none (0), present but not disturbing (1), disturbing (2),
or very disturbing (3), and a total severity score was calculated
using the sum of the scores for each symptom]; ocular signs on
slit-lamp examination [conjunctival hyperemia was scored
using the McMonnies scale (0 to 5) and ocular staining using
the Oxford (0 to 15) grading scheme]; corneal thickness; fun-
doscopy; visual field examinations; best-corrected far visual
acuity using a Snellen chart; blood pressure and heart rate; and
investigator-reported and patient-reported satisfaction of local
tolerance (rated as very satisfactory, satisfactory, not very
satisfactory, or unsatisfactory).
Statistical Analyses
The primary objective of this study was to demonstrate
noninferiority of T2347 versus BPLT in terms of the change
from baseline (D0) in mean IOP on D84 in the worse eye. The
noninferiority test was based on the 95% confidence interval
(CI) of the difference between the 2 groups (T2347 minus
BPLT) using a mixed model for repeated measures (MMRM),
including treatment, visit, treatment by visit interaction, and
baseline IOP by visit interaction adjusted for baseline IOP and
country. Noninferiority was concluded if the upper bound of
the 95% CI for the difference was <+1.5mmHg. Sensitivity
analyses [analysis of covariance (ANCOVA)] based on the last-
observation-carried-forward method were performed to explore
any possible impact of the dropout pattern on the non-
inferiority analysis. Treatment comparisons for the secondary
efficacy endpoints and the safety endpoints were performed
using ANCOVA for quantitative parameters or the Cochran-
Mantel-Haenszel (CMH) test for ordered qualitative parame-
ters. As changes from baseline in total subjective ocular
symptoms score were not normally distributed, the changes in
total symptoms scores were assessed on the basis of 3 classes
[improvement (<0)/no change (0)/worsening (>0)] and com-
pared between treatment groups using a CMH test with
modified ridit scores stratified by country (post hoc analyses).
A total of 194 patients (97 patients in each treatment
group) evaluable for the efficacy analysis would provide
90% power for the noninferiority calculation, assuming no
difference between the groups and a standard deviation of
3.2 mmHg for the primary efficacy variable. Assuming a
dropout rate of 7%, it was planned to enroll a total of 210
patients (105 in each group).
Efficacy analyses were performed using the modified
intent-to-treat (mITT) set (all randomized patients who
received at least one dose and had at least one postbaseline
efficacy evaluation); the primary efficacy analysis was con-
firmed using the per protocol (PP) set (all mITT patients
without a major protocol deviation) and ITT set (all
randomized patients who received at least one dose). Safety
analyses were performed using the safety set (all enrolled
patients who received at least one dose).
RESULTS
Patients
Overall, 242 patients were randomized at D0 to receive
T2347 (N= 127) or remain on BPLT treatment (N= 115)
(ITT set; Fig. 1). Of them, 122 and 110 patients, respec-
tively, completed the study. All enrolled patients had well-
controlled IOP before inclusion in the study
(15.7 ± 2.4 mmHg overall before inclusion) (Table 1) and at
baseline (15.6 ± 2.1 and 15.7 ± 2.1 mmHg, in the T2347 and
BPLT groups, respectively) (Table 2). There were no









Male 47 (37.0) 46 (40.0) 93 (38.4)
Female 80 (63.0) 69 (60.0) 149 (61.6)
Age (y)
Mean±SD 65.8± 10.8 67.2± 10.6 66.4± 10.7
Range 27-87 35-91 27-91
Diagnosis, n (%)
OAG 95 (74.8) 99 (86.1) 194 (80.2)
OHT 32 (25.2) 16 (13.9) 48 (19.8)
Diagnosis category, n (%)
Exfoliative
glaucoma
7 (5.5) 7 (6.1) 14 (5.8)
Pigmentary
glaucoma
1 (0.8) 1 (0.9) 2 (0.8)
Primary OAG/
OHT
119 (93.7) 107 (93.0) 226 (93.4)
Time from diagnosis (mo)
Mean±SD 103.2± 72.3 91.2± 81.1 97.5± 76.7
Corneal thickness (µm)
Mean±SD 546.7± 27.2 549.5± 26.0 548± 26.6
Fundoscopy (C/D ratio)
Mean±SD 0.50± 0.21 0.51± 0.22 0.50± 0.21
< 0.7, n (%) 95 (74.8) 81 (70.4) 176 (72.7)
≥ 0.7, n (%) 32 (25.2) 34 (29.6) 66 (27.3)
IOP history
IOP with monotherapy (before combination therapy)
n† 92 89 181
Mean ± SD
(mm Hg)
21.1± 3.5 20.5± 3.4 20.8± 3.5
[95% CI] [20.3, 21.8] [19.7, 21.2] [20.3, 21.3]
IOP with combination therapy* (before inclusion in the study)
n† 110 101 211
Mean±SD
(mmHg)
15.8± 2.5 15.6± 2.4 15.7± 2.4
[95% CI] [15.3, 16.3] [15.1, 16.0] [15.4, 16.0]
*Within 6 months.
†n= number of patients with available data.
C/D indicates cup to disc ratio; CI, confidence interval; IOP, intraocular
pressure; N, number of patients in group; OAG, open-angle glaucoma; OHT,
ocular hypertension.
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relevant differences between groups for demography and
baseline assessments (Table 1).
Efficacy
Primary Efficacy Variable
The mean change in IOP at D84 was −0.49±1.80mmHg
for T2347 and −0.49±2.25mmHg for BPLT in the mITT
set (Table 2). Noninferiority was demonstrated at D84, as
the upper limit of the 95% CI for the difference between treat-
ments (T2347 minus BPLT) was <1.5mmHg (0.50mmHg,
MMRM). Noninferiority was confirmed by the PP and ITT
analyses.
The sensitivity analysis using ANCOVA also supported
the result of noninferiority (upper 95% CI: 0.54mmHg).
Secondary Efficacy Variables
In the contralateral eye, the change in IOP from baseline at
D84 was 0.08±2.06mmHg for T2347 and 0.14±2.25mmHg
for BPLT, with an upper 95% CI for the treatment difference of
0.43mmHg (MMRM), supporting the primary analysis. The
sensitivity analysis for the contralateral eye (ANCOVA) also
supported the primary analysis (upper 95% CI: 0.44mmHg).
Similar results were seen at D42 in the worse eye, with
a change in IOP of −0.65± 1.86 mmHg for T2347 and
−0.49± 2.24 mmHg for BPLT (upper 95% CI: 0.31 mmHg)
(Table 2). Results for the contralateral eye also showed no
difference between groups at D42, supporting the results for
the worse eye, with a change in IOP of 0.05± 2.41 mmHg
for T2347 and 0.05 ± 2.18 mmHg for BPLT (upper 95% CI:
0.52 mmHg).
Investigators assessed the global efficacy as satisfactory
or very satisfactory with no statistically significant difference
between treatments at D42 (≥ 94.6%; P= 0.850, CMH) and
D84 (≥ 97.5%; P= 0.862).
Safety and Tolerability
Adverse Events
In the T2347 group, 12 (9.4%) patients experienced
treatment-related ocular AEs versus 8 (7.0%) patients in the
BPLT group (P= 0.482). The most common treatment-
related ocular AEs were eye irritation (2 and 5 patients in
the T2347 and BPLT groups, respectively) and conjunctival
hyperemia (3 and 1 patients) (Table 3). The incidence of
treatment-related systemic AEs was similar in both treat-
ment groups (P= 0.686), reported by 4 (3.1%) patients in the
T2347 group and 2 (1.7%) patients in the BPLT group
(Table 3).
Most treatment-related ocular and systemic AEs were
mild or moderate in severity. No patient in either group
experienced an ocular SAE; one patient experienced a sys-
temic SAE (cerebral artery occlusion in the BPLT group),
but this was not considered to be treatment related, and
the patient recovered without sequelae. Three patients were





































FIGURE 1. Patient disposition.
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eye pain (one patient in the T2347 group) and eye irritation
(one patient in each group).
Ocular Symptoms
The median (range) total severity score of ocular
symptoms upon instillation was similar at baseline in the
T2347 group and the BPLT group (1.0 [0-9] for both), and
it was consistently lower for T2347 than for BPLT on D42
(0.0 [0-9] vs. 1.0 [0-6]) and D84 (0.0 [0-6] vs. 0.5 [0-7]). A
statistically significant between-group difference was shown
for the change from baseline in the total score of symptoms
upon instillation on D42 (P= 0.007), as well as on D84
(P= 0.021) (Table 4). No statistically significant between-
group difference was shown for ocular symptoms through-
out the day on D42 (P= 0.155) and D84 (P= 0.129)
(Table 4).
There were no statistically significant differences between
treatments in individual ocular symptoms of tearing, foreign
body sensation, and eye dryness sensation on D42 or D84,
either upon instillation or throughout the day (Fig. 2 and
Table, Supplemental Digital Content 1, http://links.lww.com/
IJG/A245). However, irritation/burning/stinging was sig-
nificantly less severe in the worse eye for T2347 than for BPLT
upon instillation on D42 (P= 0.003) and D84 (P< 0.001)
(Fig. 2A), but there was no difference between treatments
throughout the day on D42 (P= 0.612) or D84 (P= 0.094)
(Fig. 2B). Itching in the worse eye on D84 was significantly
less severe for T2347 than for BPLT, both upon instillation
(P= 0.01) (Fig. 2A) and throughout the day (P< 0.001)
(Fig. 2B).
Other Safety Parameters
There were no clinically important differences between
groups for any slit-lamp examination, including conjunctival
hyperemia and global ocular staining (Table 4), nor for cor-
neal thickness, fundoscopy, visual field examinations, best-
corrected far visual acuity, blood pressure, or heart rate dur-
ing the study.
Satisfaction with regard to local tolerance assessed by
the investigator and patient was similar for each group at
both D42 (≥ 96.4% very satisfactory/satisfactory, P= 0.442
and P= 0.110, respectively) and at D84 (≥ 93.6% very sat-
isfactory/satisfactory, P= 0.058 and P= 0.089). Of note, the
percentage of patients who were very satisfied was higher in
the T2347 group than in the BPLT group on both D42
(57.0% vs. 45.0%) and D84 (65.3% vs. 50.0%).
DISCUSSION
In this phase III randomized, investigator-masked, and
multicenter study, noninferiority of efficacy for a preservative-free
latanoprost-timolol fixed combination (T2347) compared with
BPLT was demonstrated at D84 in patients suffering fromOAG/
OHT who were previously receiving the preserved formulation.
Although the overall safety profile was comparable between the 2
groups, T2347 induced improvements in some ocular symptoms.
Although an increased bioavailability of BAK-
preserved drugs has been reported,26–28 a growing body of
evidence indicates no difference between BAK-preserved
and BAK-free formulations. Comparable penetration of
both tafluprost formulations has been shown in the aqueous
humor of rabbits.29 Furthermore, numerous clinical trials
have assessed the impact on efficacy of the removal of BAK
from latanoprost,25 bimatoprost,30 tafluprost,31 timolol,32 or
bimatoprost/timolol fixed combination33,34 formulations
and concluded that the efficacy of the BAK-free formulation
was noninferior (or equivalent) to that obtained with the
BAK-preserved formulation. Recently, Bhagat and col-
leagues performed a randomized, parallel-group, active-
controlled study in patients with OAG or OHT to compare
the IOP-lowering efficacy of a novel fixed-dose combination
of latanoprost 0.005%/timolol 0.5%, preserved with zinc
chloride and boric acid, with latanoprost (BAK-preserved,
Xalatan; Pfizer Inc., New York, NY) or timolol (BAK-
preserved, Timoptic; Merck & Co Inc., Whitehouse Station,
NJ) administered as monotherapy or concomitantly.23 The
IOP-lowering efficacy of this new BAK-free latanoprost/
timolol fixed combination was similar to BAK-preserved
latanoprost plus timolol administered concomitantly, and
better than preserved latanoprost or timolol administered
alone. Our results are consistent with the literature and add
to these previous findings in terms of IOP control. Of note,
TABLE 2. Intraocular Pressure (mmHg) in the Worse Eye at Day 0, Day 42, and Day 84 (mITT Set)
Timepoint Statistics T2347 (N= 124) BPLT (N= 112)
Day 0 (baseline) n 124 112
Mean±SD 15.6± 2.1 15.7± 2.1
Day 42 n 123 112
Mean±SD 15.0± 2.3 15.2± 2.4
Change from baseline Mean±SD −0.65± 1.86 −0.49± 2.24
95% CI [−0.98; −0.32] [−0.91; −0.07]
Statistical analysis Adjusted mean±SE −0.68± 0.18 −0.48± 0.19
Adjusted mean difference ± SE −0.19± 0.25
95% CI [−0.69; 0.31]
Day 84 (primary efficacy analysis) n 122 110
Mean±SD 15.1± 2.4 15.2± 2.2
Change from baseline Mean±SD −0.49± 1.80 −0.49± 2.25
95% CI [−0.81; −0.17] [−0.92; −0.07]
Statistical analysis Adjusted mean±SE −0.51± 0.18 −0.52± 0.19
Adjusted mean difference ± SE 0.01± 0.25
95% CI [−0.48; 0.50]
Adjusted mean difference= (T2347 minus BPLT).
CI indicates confidence interval; N, number of patients in the group; n, number of patients with evaluable data; SE, standard error.
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the slight IOP reduction in patients who continued on the
same treatment during the study (BPLT group) could be
explained by the lack of reproducibility in diurnal IOP
pattern over time35,36 or by the Hawthorne effect, that is,
better patient management and overall compliance in a
clinical trial setting.37,38
Formulations without preservatives have previously
been shown to have improved tolerability compared with
those containing BAK.25 In the present study, however,
preservative-free T2347 showed a similar overall safety
profile to the BAK-preserved comparator. At least 4 possi-
ble explanations can be put forward for this observation.
First, an 84-day treatment period may not be sufficient to
observe real differences in objective ocular signs. For
instance, in another 3-month study, a BAK-preserved for-
mulation of travoprost showed a similar safety profile to a
BAK-free formulation.39 In clinical practice, glaucoma
treatment is usually given over a period of years, and the
toxic effects of BAK may require regular use over a long
period of time before adverse ocular signs are clinically
identifiable.20,40 Second, although the combination of 2
ocular therapies might be expected to result in a safety
profile reflecting the sum of side effects due to the individual
components, clinical studies and meta-analyses have shown
fixed combinations containing a β-blocker to be better tol-
erated than individual components.15,16,41,42 In this context,
it is noteworthy that local tolerance, including moderate to
severe conjunctival hyperemia, has been shown to be sig-
nificantly improved by the same preservative-free for-
mulation as T2347 but without timolol (Monoprost; Labo-
ratoires Théa, Clermont-Ferrand, France) compared with
BPLT without timolol (Xalatan) after 3 months of
treatment.25 The presence of timolol in the latanoprost
formulations, therefore, could reduce the between-group
difference in tolerability in the present study that would
otherwise be expected due to the preservative. Third,
patients with a more severe ocular surface disease were not
included in the present study. Exclusion of these potentially
more sensitive patients could have further limited the
TABLE 3. Summary of AEs Related to Treatment (Safety Set)
T2347 (N= 127) BPLT (N= 115)
Preferred Term No. AEs
Patients
[n (%)] No. AEs
Patients
[n (%)]
Ocular AEs 14 12 (9.4) 14 8 (7.0)
Eye irritation 2 2 (1.6) 5 5 (4.3)
Conjunctival
hyperemia
3 3 (2.4) 1 1 (0.9)
Eye pain 2 2 (1.6)* 0 0
Eye allergy 0 0 3 1 (0.9)
Eye discharge 0 0 1 1 (0.9)
Foreign body
sensation in eyes
0 0 1 1 (0.9)
Keratitis 0 0 1 1 (0.9)
Lacrimation increased 0 0 1 1 (0.9)
Intraocular pressure
increased
0 0 1 1 (0.9)
Blepharitis 1 1 (0.8) 0 0
Conjunctivitis staining 1 1 (0.8) 0 0
Eye pruritus 1 1 (0.8) 0 0
Ocular hyperaemia 1 1 (0.8) 0 0
Optic disc hemorrhage 1 1 (0.8)* 0 0
Papilloma
conjunctival
1 1 (0.8)* 0 0
Visual acuity reduced 1 1 (0.8) 0 0
Systemic AEs 4 4 (3.1) 2 2 (1.7)
Heart rate irregular 0 0 1 1 (0.9)
Myalgia 0 0 1 1 (0.9)*
Arrhythmia 1 1 (0.8) 0 0
Dysgeusia 1 1 (0.8) 0 0
Fatigue 1 1 (0.8) 0 0
Rhinorrhea 1 1 (0.8)* 0 0
Preferred term coding according to the Medical Dictionary for Regu-
latory Activities Version 16.1 (September 2013).
Data are the number of events and number of patients (%) with at least
one treatment-related (unlikely, possible, or definite) episode.
*Relationship to treatment rated as unlikely (relationship of one of the
two episodes of eye pain [T2347 group] rated as unlikely).
N indicates the number of patients in the group.
TABLE 4. Summary of Main Ocular Safety Assessments (Safety set)
Change From Baseline (in 3 classes)
Total Symptom Score Ocular Signs
Upon Instillation Throughout the Day Conjunctival Hyperaemia Global Ocular Staining
T2347 BPLT T2347 BPLT T2347 BPLT T2347 BPLT
Day 42
n 122 112 122 111 123 112 123 112
Improvement 54 (44.3) 30 (26.8) 48 (39.3) 37 (33.3) 35 (28.5) 19 (17.0) 40 (32.5) 33 (29.5)
No change 48 (39.3) 55 (49.1) 63 (51.6) 60 (54.1) 77 (62.6) 83 (74.1) 62 (50.4) 60 (53.6)
Worsening 20 (16.4) 27 (24.1) 11 (9.0) 14 (12.6) 11 (8.9) 10 (8.9) 21 (17.1) 19 (17.0)
P 0.007 0.155 0.135 0.535
Day 84
n 122 110 122 110 123 112 122 110
Improvement 56 (45.9) 37 (33.6) 50 (41.0) 42 (38.2) 39 (32.0) 23 (20.9) 42 (34.4) 42 (38.2)
No change 54 (44.3) 52 (47.3) 65 (53.3) 51 (46.4) 73 (59.8) 75 (68.2) 62 (50.8) 52 (47.3)
Worsening 12 (9.8) 21 (19.1) 7 (3.0) 17 (15.5) 10 (8.2) 12 (10.9) 18 (14.8) 16 (14.5)
P 0.021 0.129 0.065 0.883
Data are number (%) of patients.
Number of patients in group: N= 127 for T2347 group; N= 115 for BPLT group.
n indicates number of patients with available data.
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differences observed between groups over the 84-day study
period. Finally, only patients already successfully treated
with a preserved latanoprost-timolol fixed combination were
included, and, by definition, these patients tolerated it well.
A potential limitation of the present study was the choice
of a single morning IOP assessment for comparing T2347 to
the preserved comparator. However, this approach is sup-
ported by several arguments: (1) peak IOP generally occurs in
the morning in most POAG and OHT patients, (2) the 24-hour
efficacy on IOP of the latanoprost-timolol fixed combination
administered once daily in the evening in glaucoma and OHT
patients is well established, (3) on the basis of preclinical data
in monkeys, T2347 was shown as effective as BPLT in
reducing IOP in the morning, as well as over 24 hours, after
once-daily repeat dosing in the evening.43 In the preclinical
study, the morning time point was shown to be the most
challenging time to demonstrate noninferiority of T2347 to the
reference treatment. This is consistent with the results from a
cross-over clinical trial that showed a similar diurnal IOP-
lowering effect (measured at 8 AM, 12 noon, 4 PM, and 8 PM) of
the same preservative-free formulation as T2347 but without
timolol (Monoprost) in comparison with BPLT without tim-
olol (Xalatan).44 Thus, it was considered that the IOP-lowering
effect of T2347 compared with the reference BPLT could
be relevantly extrapolated from the single morning IOP
assessment.
Other potential limitations of the study included a double-
masked design not being feasible due to the different packaging
of T2347 and BPLT (single-dose units vs. multidose vials,
respectively). Although the study procedures ensured that sin-
gle-masking was maintained and controlled by assigning per-
sonnel other than the investigator to dispense treatments and by
instructing patients not to disclose treatment information to the
investigator, patients could have known which treatment was
assigned, which could have led to bias in the reporting of
subjective assessments. Also, for ethical purposes, a washout
period was deemed not to be appropriate for these patients
already treated and IOP controlled by preserved fixed combi-
nation at study entry. Moreover, the primary endpoint was
evaluated at D84, allowing sufficient time to eliminate any
carry-over effect of previous treatment. With regard to the
statistical tests, an upper 95% CI limit of 1.5mmHg for the
treatment difference at D84 was used to show noninferiority for
the IOP change from baseline for T2347 compared with BPLT.
While 1.5mmHg is a common limit for studies with partic-
ipants with uncontrolled IOP at baseline,15,45 using it for par-
ticipants already medicated at study entry and therefore with
lower IOP at baseline, such as in the present study, could be
considered a less rigorous standard. However, the non-
inferiority of T2347 would still have been demonstrated using
the more stringent limit of 1mmHg,46,47 and even using





























FIGURE 2. Individual ocular symptoms at day 84. Individual ocular symptom scores upon instillation (A) and throughout the day (B)
were compared between groups using a Cochran Mantel Haenszel test with modified ridit scores stratified by country. *P=0.01;
**P<0.001 (see also Supplement Table for details, Supplemental Digital Content 1, http://links.lww.com/IJG/A245).
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although the study was not designed for a formal noninferiority
assessment at this time point.
In conclusion, the preservative-free latanoprost-timolol
fixed combination T2347 showed noninferior efficacy com-
pared with the preserved comparator in patients who were
previously receiving the preserved formulation at study entry.
T2347 was well tolerated and demonstrated improvements in
some of the ocular symptoms. It could potentially confer a
therapeutic advantage for OAG/OHT patients on long-term
treatment.
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